

<u>Last Name</u>	<u>First Name</u>	<u>Roles</u>	<u>Relationships</u>	<u>Company Name</u>	<u>Honoraria/Expenses</u>	<u>Consulting/Advisory Board</u>	<u>Funded Research</u>	<u>Royalties/Patent</u>	<u>Stock Options</u>	<u>Ownership/Equity Position</u>	<u>Employee</u>	<u>Other</u>	<u>Off Label Product Use</u>
Alexander	Sarah	Invited Speaker/Faculty	No										off label use of levofloxacin in pediatric oncology patients
Armenian	Saro	Invited Speaker/Faculty	No										
Bisogno	Gianni	Invited Speaker/Faculty	Yes	Bayer		X							
Broutier	Laura	Invited Speaker/Faculty	No										
Brugières	Laurence	Invited Speaker/Faculty	Yes	Takeda		X							
				Bristol-Myers Squibb			X						
Czauderna	Piotr	Invited Speaker/Faculty	No										Sodium Thiosulfate on the occasion of the SIOPEL 6 study summary
Dalvi	Rashmi	Board of Directors	No										
Day	Sarah	Invited Speaker/Faculty	No										
Doz	Francois	Invited Speaker/Faculty Poster/Oral Presenter	No										
Durand	Chantal	Invited Speaker/Faculty	No										
Faure Conter	Cécile	Invited Speaker/Faculty Session Moderator/Chair/Coordinator	No										
Figarella-Branger	Dominique	Invited Speaker/Faculty Poster/Oral Presenter	Yes	Novartis								pathological analysis of pituitary adenomas included in the EALIA study	
Fisher	Brian	Invited Speaker/Faculty	Yes	Astellas Pharma		X							This is a talk about novel therapies for C. difficile infection. As such I will discuss therapies that have been approved for use in adults such as fidaxomicin but no approval yet in kids. Additionally, I will discuss agents that may be available in the future such as monoclonal antibodies.
				Pfizer			X						This is a talk about novel therapies for C. difficile infection. As such I will discuss therapies that have been approved for use in adults such as fidaxomicin but no approval yet in kids. Additionally, I will discuss agents that may be available in the future such as monoclonal antibodies.

<u>Last Name</u>	<u>First Name</u>	<u>Roles</u>	<u>Relationships</u>	<u>Company Name</u>	<u>Honoraria/Expenses</u>	<u>Consulting/Advisory Board</u>	<u>Funded Research</u>	<u>Royalties/Patent</u>	<u>Stock Options</u>	<u>Ownership/Equity Position</u>	<u>Employee</u>	<u>Other</u>	<u>Off Label Product Use</u>
				Merck			X						This is a talk about novel therapies for C. difficile infection. As such I will discuss therapies that have been approved for use in adults such as fidaxomicin but no approval yet in kids. Additionally, I will discuss agents that may be available in the future such as monoclonal antibodies.
Frappaz	Didier	Invited Speaker/Faculty	No										
Fuchs	Joerg	Invited Speaker/Faculty Session Moderator/Chair/Coordinator	No										
Geoerger	Birgit	Invited Speaker/Faculty Poster/Oral Presenter	No										ribociclib, olaparib, AZD1775, nivolumab, everolimus, enasidenib
Gessler	Manfred	Invited Speaker/Faculty	No										
Grundy	Richard	Scientific/Education Planning Committee Session Moderator/Chair/Coordinator Committee (CME Research other)	No										
Hawkins	Doug	Invited Speaker/Faculty	Yes	Bayer	X	X	X						Irinotecan, temsirolimus
				Loxo Oncology	X	X	X						Irinotecan, temsirolimus
				celgene	X	X							Irinotecan, temsirolimus
				Bristol-Myers Squibb	X	X	X						Irinotecan, temsirolimus
				Merck			X						Irinotecan, temsirolimus
				Lilly			X						Irinotecan, temsirolimus
Hunger	Stephen	Scientific/Education Planning Committee Invited Speaker/Faculty Session Moderator/Chair/Coordinator	Yes	Amgen	X					X		I own common stock in Amgen	
Kolb	Frederic	Invited Speaker/Faculty	No										
Kortmann	Rolf-Dieter	Session Moderator/Chair/Coordinator	No										
Ladas	Elena	Session Moderator/Chair/Coordinator Poster/Oral Presenter	No										
Laskar	Siddhartha	Invited Speaker/Faculty Poster/Oral Presenter	No										
Lehrnbecher	Thomas	Invited Speaker/Faculty	Yes	Merck	X	X							Fidaxomicin, fecal microbiota transplantation, actoxumab, bezlotoxumab
				Gilead Sciences	X	X	X						Fidaxomicin, fecal microbiota transplantation, actoxumab, bezlotoxumab

<u>Last Name</u>	<u>First Name</u>	<u>Roles</u>	<u>Relationships</u>	<u>Company Name</u>	<u>Honoraria/ Expenses</u>	<u>Consulting/ Advisory Board</u>	<u>Funded Research</u>	<u>Royalties/ Patent</u>	<u>Stock Options</u>	<u>Ownership/ Equity Position</u>	<u>Employee</u>	<u>Other</u>	<u>Off Label Product Use</u>
				Astellas Pharma	X								Fidaxomicin, fecal microbiota transplantation, actoxumab, bezlotoxumab
													Fidaxomicin, fecal microbiota transplantation, actoxumab, bezlotoxumab
Lobos	Pablo	Scientific/Education Planning Committee Session Moderator/Chair/Coordinator	No										
Mabbot	Donald	Invited Speaker/Faculty	No										Metformin
Mandeville	Henry	Invited Speaker/Faculty	No										
Marabelle	Aurelien	Invited Speaker/Faculty Poster/Oral Presenter	No										
Massimino	Maura	Invited Speaker/Faculty	No										
Moreno Ramirez	Arturo	Board of Directors	No										
Nahata	Leena	Invited Speaker/Faculty	No										
Olsson	Maria	Invited Speaker/Faculty	No										
Pergert	Pernilla	Scientific/Education Planning Committee Session Moderator/Chair/Coordinator	No										
Pfister	Stefan	Invited Speaker/Faculty	No										
Phillips	Bob	Invited Speaker/Faculty	No										
Raetz	Elizabeth	Invited Speaker/Faculty	Yes	Pfizer			X						I will be referencing investigational uses of immunotherapeutics
Ramaswamy	Vijay	Invited Speaker/Faculty	Yes	AstraZeneca	X								
Sarnacki	Sabine	Invited Speaker/Faculty	No										
Schleiermacher	Gudrun	Invited Speaker/Faculty	Yes	Bristol-Myers Squibb	X		X						
				Merck			X						
				Pfizer			X						
				Hoffmann-La Roche			X						
Schrapppe	Martin	Invited Speaker/Faculty	Yes	Servier Laboratories	X								
				Jazz			X						
				Amgen								Drug supply	
Sung	Lillian	Scientific/Education Planning Committee Invited Speaker/Faculty	No										
Tirode	Franck	Invited Speaker/Faculty	No										
Trehan	Amita	Invited Speaker/Faculty	No										
Van Den Heuvel-Eibrink	Marry	Scientific/Education Planning Committee	No										
Vassal	Gilles	Invited Speaker/Faculty	No										
Viani	Karina	Invited Speaker/Faculty Poster/Oral Presenter	No										
Weiderpasse	Elisabete	Invited Speaker/Faculty	No										
Witt	Olaf	Invited Speaker/Faculty	No										
Zernikow	Boris	Invited Speaker/Faculty	Yes	Grunenthal		X						Head Data Management Committee	Larotrectinib